<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044860</url>
  </required_header>
  <id_info>
    <org_study_id>Endocrinemapping</org_study_id>
    <nct_id>NCT03044860</nct_id>
  </id_info>
  <brief_title>Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes</brief_title>
  <official_title>Enteroendocrine Cells in Healthy Individuals and Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the anatomical distribution of enteroendocrine cells by a systematic&#xD;
      approach along the entire human intestinal tract in healthy individuals and patients with&#xD;
      type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enteroendocrine K and L cells are pivotal in regulating appetite and glucose homeostasis, but&#xD;
      knowledge of their distribution in man is sparse and it is unknown whether alterations occur&#xD;
      in type 2 diabetes. Twelve patients with type 2 diabetes and 12 age and BMI-matched healthy&#xD;
      individuals underwent upper and lower double-balloon enteroscopy with mucosal biopsy&#xD;
      retrieval from every ~30 cm of the small intestine and specific locations in the large&#xD;
      intestine. The investigators evaluated the distribution of enteroendocrine cells (using IHC&#xD;
      staining for their specific hormonal products) and evaluated mRNA expression of the&#xD;
      corresponding genes along the entire intestinal tract in patients with type 2 diabetes and in&#xD;
      healthy individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of enteroendocrine cells (density and mRNA expression) in the intestinal tract.</measure>
    <time_frame>Cross-sectional study. Each participant went through two study days (upper and lower double-ballon enteroscopy, respectively)</time_frame>
    <description>Using a double-balloon enteroscopy device, mucosal biopsies are obtained from the entire intestinal tract in 12 healthy individuals and 12 patients diagnosed with type 2 diabetes. The biopsies are analysed using immunohistochemistry (IHC) and mRNA expression analysis.&#xD;
Positively stained enteroendocrine cells (from IHC) are counted and divided by the epithelial area providing 'density' (cells/mm2).&#xD;
The data obtained from cell count and mRNA expression analysis present the variation in number of enteroendocrine cells (density) and the expression of hormonal products along the intestinal tract.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of differences in enteroendocrine cells (density and mRNA expression) along the intestinal tract of healthy individuals compared with type 2 diabetes patients.</measure>
    <time_frame>Cross-sectional study. Each participant went through two study days (upper and lower double-ballon enteroscopy, respectively)</time_frame>
    <description>Using a double-balloon enteroscopy device, mucosal biopsies are obtained from the entire intestinal tract in 12 healthy individuals and 12 patients diagnosed with type 2 diabetes. The biopsies are analysed using immunohistochemistry (IHC) and mRNA expression analysis.&#xD;
Positively stained enteroendocrine cells (from IHC) are counted and divided by the epithelial area providing 'density' (cells/mm2).&#xD;
Cell count (density) and mRNA expression data obtained from the healthy individuals and type 2 diabetes patietns are compared to evaluate potential differences between the two groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Double-balloon enteroscopy (DBE) with biopsy retrieval</intervention_name>
    <description>With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every ~30 cm of the small intestine and specific locations in the large intestine</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Type 2 diabetes patients&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes (at least 3 months prior to study inclusion)&#xD;
&#xD;
          -  Treatment with diet counseling alone or combined with an glucose-lowering drugs:&#xD;
             metformin or sulphonylurea&#xD;
&#xD;
          -  Caucasian ethnicity&#xD;
&#xD;
          -  Age &gt;25 and &lt;70 years&#xD;
&#xD;
          -  Normal hemoglobin&#xD;
&#xD;
          -  Negative for autoantibodies to glutamic acid decarboxylase (GAD-65) and islet cell&#xD;
             autoantibodies (ICA).&#xD;
&#xD;
        Healthy individuals&#xD;
&#xD;
          -  Fasting plasma glucose &lt;6.0 mM&#xD;
&#xD;
          -  Plasma glucose 2 hours after a 75 g-oral glucose tolerance test &lt;7.8 mM&#xD;
&#xD;
          -  Negative for GAD-65 antibodies and ICA&#xD;
&#xD;
          -  Caucasian ethnicity&#xD;
&#xD;
          -  Age &gt;25 and &lt;70 years&#xD;
&#xD;
          -  Normal hemoglobin&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Type 2 diabetes patients&#xD;
&#xD;
          -  Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase&#xD;
             &gt;2 times normal value)&#xD;
&#xD;
          -  Treatment with dipeptidyl peptidase 4 inhibitors or medicine that could not be paused&#xD;
             for 12 hours&#xD;
&#xD;
          -  Previous hysterectomy, appendectomy, cholecystectomy or caesarean&#xD;
&#xD;
          -  Sleep apnea&#xD;
&#xD;
          -  American Society of Anesthesiologists class &gt;3&#xD;
&#xD;
          -  Allergy to soy protein or eggs&#xD;
&#xD;
          -  BMI &gt;35 kg/m2 or any other condition that would contraindicate propofol sedation or&#xD;
             enteroscopy.&#xD;
&#xD;
        Healthy individuals&#xD;
&#xD;
          -  Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase&#xD;
             &gt;2 times normal value)&#xD;
&#xD;
          -  Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase&#xD;
             &gt;2 times normal value)&#xD;
&#xD;
          -  Treatment with dipeptidyl peptidase 4 inhibitors or medicine that could not be paused&#xD;
             for 12 hours&#xD;
&#xD;
          -  Previous hysterectomy, appendectomy, cholecystectomy or caesarean&#xD;
&#xD;
          -  Sleep apnea&#xD;
&#xD;
          -  American Society of Anesthesiologists class &gt;3&#xD;
&#xD;
          -  Allergy to soy protein or eggs&#xD;
&#xD;
          -  BMI &gt;35 kg/m2 or any other condition that would contraindicate propofol sedation or&#xD;
             enteroscopy&#xD;
&#xD;
          -  First-degree relative(s) with type 1 or type 2 diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>MD, PhD, professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

